Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
CAMBRIDGE, Mass., Jan. 03, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2017 at 10:00 a.m. PT (1:00 p.m. ET).
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Contacts Investors: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
